Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lenvatinib Plus Bevacizumab and a PD-1 Inhibitor in Unresectable Hepatocellular Carcinoma
NCT07870772Phase 2Not yet recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Oct 2026
- Primary completion
- Jun 2027
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of lenvatinib in hepatocellular carcinoma (HCC) (2 arms), sponsored by Sun Yat-sen University. Primary endpoints: Overall Survival at 6 months and Progression-Free Survival at 6 months. Planned start Oct 2026; status: not yet recruiting.
02
Drugs
lenvatinib
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT07870772.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07870772.